Description
Roxatidine (78273-80-0) is a novel histamine H2 receptor antagonist.1Suppresses inflammatory responses via inhibition of NFκB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages.2Clinically useful agent for prevention and healing of gastric and duodenal ulcers and bleeding.3Attenuates degradation of extracellular matrix in osteoarthritis models by inactivating the NFkB pathway.4
References
[1] J G MILLS J R W. The pharmacology of histamine H2-receptor antagonists.[J]. Methods and findings in experimental and clinical pharmacology, 1989, 11 Suppl 1: 87-95.
[2] EU-JIN CHO. Roxatidine suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages†[J]. Journal of cellular biochemistry, 2011, 112 12: 3648-3659. DOI:
10.1002/jcb.23294[3] HIROYUKI IMAEDA. Effect of lansoprazole versus roxatidine on prevention of bleeding and promotion of ulcer healing after endoscopic submucosal dissection for superficial gastric neoplasia.[J]. Journal of Gastroenterology, 2011, 46 11: 1267-1272. DOI:
10.1007/s00535-011-0447-1[4] RENHAO ZE. Roxatidine Attenuates Degradation of Extracellular Matrix.[J]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017: 1156-1160. DOI:
10.1016/j.biopha.2017.08.130
